Cargando…

Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma

BACKGROUND: The expression levels of Programmed death ligand-1 (PD-L1), epidermal growth factor receptor (EGFR), anaplastic lymphoma tyrosine kinase gene (ALK), and proto-oncogene tyrosine-protein kinase 1 ROS (ROS1) are important for targeted treatment selection in advanced lung cancer. Most patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Ekin, Zübeyde, Nart, Deniz, Savaş, Pınar, Veral, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Trakya University School of Medicine 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880835/
https://www.ncbi.nlm.nih.gov/pubmed/34558414
http://dx.doi.org/10.5152/balkanmedj.2021.20086
_version_ 1784659320187650048
author Ekin, Zübeyde
Nart, Deniz
Savaş, Pınar
Veral, Ali
author_facet Ekin, Zübeyde
Nart, Deniz
Savaş, Pınar
Veral, Ali
author_sort Ekin, Zübeyde
collection PubMed
description BACKGROUND: The expression levels of Programmed death ligand-1 (PD-L1), epidermal growth factor receptor (EGFR), anaplastic lymphoma tyrosine kinase gene (ALK), and proto-oncogene tyrosine-protein kinase 1 ROS (ROS1) are important for targeted treatment selection in advanced lung cancer. Most patients with lung cancer are diagnosed at an advanced stage and have no chance of surgery. For this reason, the accuracy and reliability of cytology samples for detecting those markers is important in patients whose histological sampling cannot be performed. AIMS: To test the compatibility of histological and cytological sample analysis results of EGFR, ALK, ROS1 and PDL-1 in patients with NSCLC and to determine the adequacy of cytological analysis for PD-L1 expression. STUDY DESIGN: Retrospective cross-sectional study. METHODS: The results of 231 patients whose PD-L1 was studied in 2018 were analyzed retrospectively. We excluded 11 inappropriate samples. A total of 220 samples were distributed as follows; 66 (30.0%) cytology specimens, 64 (29.1%) small histology biopsies, and 90 (40.9%) surgical biopsies. EGFR, ALK, ROS1 and PD-L1 analysis were performed in 139, 134, 116, and 220 patients, respectively. Samples containing >400 cells were considered suitable for molecular cytological study. RESULTS: A total of 154 (70.0%) histological (surgical biopsy) and 66 (30.0%) cytology samples were analyzed. There was no statistically significant difference between histological and cytological samples in terms of cellular adequacy for all molecular markers [EGFR: 93.7% and 90.9% (P = .556), ALK: 97.8% and 95.3% (P = .436) , ROS1: 89.9% vs. 91.9% (P = .729), PD-L1: 95.5% vs. 92.4% (P = .364)]. There was no statistically significant difference in the expression positivity rates of all biomarkers between histological and cytological samples [EGFR: 9.0% vs. 2.5% (P = .018), ALK: 7.9% vs. 9.8% (P = .719), ROS1 : 1.4% vs. 2.9% (P = .591), PD-L1: 54.4% vs. 41.0% (P = .078)]. CONCLUSION: The cellular adequacy of cytology specimens for molecular testing in patients with NSCLC is satisfactory. This study shows that EGFR, ALK, ROS-1 and PDL-1 expression rates in cytological samples are not statistically different from histological samples.
format Online
Article
Text
id pubmed-8880835
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Trakya University School of Medicine
record_format MEDLINE/PubMed
spelling pubmed-88808352022-03-10 Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma Ekin, Zübeyde Nart, Deniz Savaş, Pınar Veral, Ali Balkan Med J Original Article BACKGROUND: The expression levels of Programmed death ligand-1 (PD-L1), epidermal growth factor receptor (EGFR), anaplastic lymphoma tyrosine kinase gene (ALK), and proto-oncogene tyrosine-protein kinase 1 ROS (ROS1) are important for targeted treatment selection in advanced lung cancer. Most patients with lung cancer are diagnosed at an advanced stage and have no chance of surgery. For this reason, the accuracy and reliability of cytology samples for detecting those markers is important in patients whose histological sampling cannot be performed. AIMS: To test the compatibility of histological and cytological sample analysis results of EGFR, ALK, ROS1 and PDL-1 in patients with NSCLC and to determine the adequacy of cytological analysis for PD-L1 expression. STUDY DESIGN: Retrospective cross-sectional study. METHODS: The results of 231 patients whose PD-L1 was studied in 2018 were analyzed retrospectively. We excluded 11 inappropriate samples. A total of 220 samples were distributed as follows; 66 (30.0%) cytology specimens, 64 (29.1%) small histology biopsies, and 90 (40.9%) surgical biopsies. EGFR, ALK, ROS1 and PD-L1 analysis were performed in 139, 134, 116, and 220 patients, respectively. Samples containing >400 cells were considered suitable for molecular cytological study. RESULTS: A total of 154 (70.0%) histological (surgical biopsy) and 66 (30.0%) cytology samples were analyzed. There was no statistically significant difference between histological and cytological samples in terms of cellular adequacy for all molecular markers [EGFR: 93.7% and 90.9% (P = .556), ALK: 97.8% and 95.3% (P = .436) , ROS1: 89.9% vs. 91.9% (P = .729), PD-L1: 95.5% vs. 92.4% (P = .364)]. There was no statistically significant difference in the expression positivity rates of all biomarkers between histological and cytological samples [EGFR: 9.0% vs. 2.5% (P = .018), ALK: 7.9% vs. 9.8% (P = .719), ROS1 : 1.4% vs. 2.9% (P = .591), PD-L1: 54.4% vs. 41.0% (P = .078)]. CONCLUSION: The cellular adequacy of cytology specimens for molecular testing in patients with NSCLC is satisfactory. This study shows that EGFR, ALK, ROS-1 and PDL-1 expression rates in cytological samples are not statistically different from histological samples. Trakya University School of Medicine 2021-09-01 /pmc/articles/PMC8880835/ /pubmed/34558414 http://dx.doi.org/10.5152/balkanmedj.2021.20086 Text en © Copyright 2021 authors https://creativecommons.org/licenses/by-nc-nd/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Original Article
Ekin, Zübeyde
Nart, Deniz
Savaş, Pınar
Veral, Ali
Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma
title Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma
title_full Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma
title_fullStr Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma
title_full_unstemmed Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma
title_short Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma
title_sort comparison of pd-l1, egfr, alk, and ros1 status between surgical samples and cytological samples in non-small cell lung carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880835/
https://www.ncbi.nlm.nih.gov/pubmed/34558414
http://dx.doi.org/10.5152/balkanmedj.2021.20086
work_keys_str_mv AT ekinzubeyde comparisonofpdl1egfralkandros1statusbetweensurgicalsamplesandcytologicalsamplesinnonsmallcelllungcarcinoma
AT nartdeniz comparisonofpdl1egfralkandros1statusbetweensurgicalsamplesandcytologicalsamplesinnonsmallcelllungcarcinoma
AT savaspınar comparisonofpdl1egfralkandros1statusbetweensurgicalsamplesandcytologicalsamplesinnonsmallcelllungcarcinoma
AT veralali comparisonofpdl1egfralkandros1statusbetweensurgicalsamplesandcytologicalsamplesinnonsmallcelllungcarcinoma